AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00001087
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00001087
Drug: Saquinavir
RxNorm normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001087
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00001087
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001087
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001087
Drug: Zalcitabine
RxNorm normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001087
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05135364
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each infusion is 30 min (not less than 20 min, not more than 60 min), once every 3 weeks
Trial: NCT05741021
Drug: F520
RxNorm normalized name: F520
DrugBank: Rulonilimab (DB18922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
Trial: NCT05741021
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A chemotherapy medication used to treat a number of types of cancer.
Trial: NCT05741021
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A chemotherapy medication used to treat a number of types of cancer.
Trial: NCT05741021
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC).
Trial: NCT04919629
Drug: Pegcetacoplan
RxNorm normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV and SC
Trial: NCT05584826
Drug: MDMA
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On 2 separate treatment visits, participants will receive dosing of 100 mg MDMA HCl (\~84 mg MDMA) + 40 mg MDMA HCl (\~34 mg MDMA) supplement unless tolerability issues arise from the first dose or the participant declines
Trial: NCT00368173
Drug: rhIGF-I/rhIGFBP-3
RxNorm normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04967690
Drug: SI-053
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SI-053 will be used as an add-on to SoC for newly diagnosed GBM.In conjunction with surgical resection, SI-053 will be applied intracranially (i.c.) into the cavity that is formed after tumor resection. Post-operative chemoradiotherapy (including concomitant and adjuvant TMZ or following the CeTeG protocol) will be initiated at least 21 and no later than 35 days after SI-053 administration.
Trial: NCT05055908
Drug: Pemetrexed plus Pembrolizumab
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc. Pemetrexed, 500mg/m2, ivgtt, every 21 days
Trial: NCT05055908
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc.
Trial: NCT05055908
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed, 500mg/m2, ivgtt, every 21 days etc.
Trial: NCT06046482
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT06046482
Drug: Magrolimab
RxNorm normalized name: Magrolimab
DrugBank: Magrolimab (DB16225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT06046482
Drug: cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT06046482
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT06047431
Drug: QL1706H
DrugBank: QL1706 (DB17562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL1706H is the subcutaneousely administered formulation of QL1706, it contains two unique monoclonal antibodies.
Trial: NCT03332888
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab will be studied in patients with HFrEF, and verify the patients safety.
Trial: NCT05250856
Drug: CNP-201
RxNorm normalized name: TransCon CNP
DrugBank: ACP-015 (DB17824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.
Trial: NCT04253132
Drug: Tolfenamic Acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid is an NSAID closely resembling mefenamic and flufenamic acid.
Trial: NCT05781048
Drug: HRS-6209
RxNorm normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-6209
Trial: NCT06488118
Drug: R848
RxNorm normalized name: Resiquimod
DrugBank: Resiquimod (DB06530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled R848 dose ranging from 0.1 to 100 μg/mL
Trial: NCT06488118
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled Saline control
Trial: NCT00002025
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05395624
Drug: 18F-OP-801
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F Hydroxyl Dendrimer
Trial: NCT06486545
Drug: Irinotecan Hydrochloride Liposome Injection；Paclitaxel For Injection (Albumin Bound)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Liposomal irinotecan, intravenous infusion 90min, d1:~Grade 1:50mg/m2； Grade 2:60mg/m2； Grade 3:70mg/m2；~Albumin-paclitaxel, 150mg/m2, intravenous infusion, d1~DLT was observed for 2 weeks (the first cycle). The same subject received only one dose of liposomal irinotecan during the study. If the patient volunteers and the investigator determines that the benefits of continuing the original regimen outweigh the risks, the subject may continue to receive treatment for metastatic disease. The drug was repeated every 2 weeks for up to 6 cycles, and the albumin paclitaxel or liposomal irinotecan were withdrawn according to the patient's adverse reactions and physical status, and the remaining single-agent maintenance therapy was performed. Until there is a possibility of surgery, disease progression, intolerable toxicity or the patient withdraws informed consent (whichever comes first).
Trial: NCT04419909
Drug: CD19 redirected autologous T cells (CTL019 or CTL119 cells)
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retreatment with CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19 cells) or huCD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19 cells) in subjects with late relapse of B-cell lymphomas.
Trial: NCT04927312
Drug: PF-06947386
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime-Avibactam powder for concentrate for solution for infusion 2.0 g/ 0.5 g. Dosage will be adjusted based on renal function after enrollment.
Trial: NCT04927312
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 0.5 g solution for injection.
Trial: NCT05627466
Drug: Magrolimab
RxNorm normalized name: Magrolimab
DrugBank: Magrolimab (DB16225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05474040
Drug: Morphine versus multimodal analgesia for post elective craniotomy pain
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To compare the effectiveness of opioid- sparing multimodal analgesia and opioid analgesia in the treatment of post-craniotomy pain
Trial: NCT05659732
Drug: PEP07
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PEP07 is a selective Chk1 inhibitor maleate drug which is supplied as a hard gelatin capsule. PEP07 will be provided as 20 mg and 150 mg strength capsules to be administrated orally. Patients allocated to different dose levels of PEP07 monotherapy will receive either 20 mg or 150 mg oral capsules for 2 consecutive days followed by 5 days treatment off (2-on/5-off) schedule every week, 4 weeks as a treatment cycle.
Trial: NCT05939284
Drug: Injection of Cetrorelix
RxNorm normalized name: cetrorelix Injection
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received Cetrorelix subcutaneous injection on the day-6 in a dose of 0.25 daily till the trigger day.
Trial: NCT05939284
Drug: Oral insertion of dydrogeserone
RxNorm normalized name: dydrogesterone Oral Tablet
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received dydrogesterone in an oral dose of 20 mg/day in parallel with gonadotropin injection from day-2 of the menstrual cycle till the trigger day
Trial: NCT05418712
Drug: VX-150
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution or Suspension for oral administration.
Trial: NCT04373603
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TXA is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, thus inhibiting degradation of fibrin clots and serving as an antifibrinolytic
Trial: NCT04373603
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronidase is a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue
Trial: NCT05116969
Drug: PTX-35
RxNorm normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody
Trial: NCT05005884
Drug: Oral intake of medication
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prescription of oral phenolics 250 mg two times daily
Trial: NCT05911022
Drug: Colchicine 0.5 MG
RxNorm normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: three times per day for three days and subsequently twice per day for four days
Trial: NCT04095858
Drug: Efprezimod alfa
RxNorm normalized name: Efprezimod alfa
DrugBank: Efprezimod alfa (DB16448)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion: 480 mg at Day -1, 240 mg at Day 14, 240 mg at Day 28.
Trial: NCT04095858
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Begin on day -3. IV \[0.03 mg/kg/day\] or PO \[0.045 mg/kg/dose\] dosing is permitted
Trial: NCT05450289
Drug: Allergen Specific Immunotherapy
RxNorm normalized name: Pacific halibut allergenic extract
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this study, we use the house dust mite allergen immunotherapy (Teaching Industry Allergen by Dr. Soetomo Hospital-Airlangga University, Surabaya, Indonesia) used was an extract of Dermatophagoides pteronyssinus via subcutaneous injection.
Trial: NCT06612086
Drug: Dapagliflozin (Forxiga)
RxNorm normalized name: dapagliflozin Oral Tablet [Farxiga]
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: we study effect of dapagliflozin on patient with pulmonary hypertension by follow up RV function and prognosis of life of patient
Trial: NCT06131918
Drug: Resveratrol, Alpha lipoic acid, Super oxide dismutase
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tab Resveratrol 1500 mg BD Tab Alpha lipoic Acid 600 mg BD Tab Superoxide dismutase 250 mg BD
Trial: NCT06131918
Drug: Resveratrol
RxNorm normalized name: Resveratrol
DrugBank: Resveratrol (DB02709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tab Resveratrol 1500 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
Trial: NCT06131918
Drug: Alpha lipoic acid
RxNorm normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tab Alpha lipoic acid 600 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
Trial: NCT06583083
Drug: Sintilimab with P-GEMOX Regimen
RxNorm normalized name: Anacin Aspirin Regimen
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab intravenous drip, Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip
Trial: NCT01969656
Drug: 2MD
RxNorm normalized name: 2MDTP
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01969656
Drug: Calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05415202
Drug: Remimazolam 20 MG [Byfavo]
RxNorm normalized name: remimazolam 20 MG [Byfavo]
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam will be administered for sedation and efficacy and safety will be recorded
Trial: NCT04972760
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib, 4 mg/d, oral route for 24 weeks
Trial: NCT00000769
Drug: Interleukin-4
RxNorm normalized name: interleukin-4
DrugBank: Binetrakin (DB12182)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05668741
Drug: IVA
RxNorm normalized name: Viva
DrugBank: Adenosine (DB00640)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration.
Trial: NCT06257212
Drug: BCG vaccine (Danish strain 1331)
RxNorm normalized name: BCG, live, Tice strain
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal BCG vaccine (0.1 ml) + subcutaneous saline at inclusion and after 3 months.
Trial: NCT06257212
Drug: MMR Vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous MMR vaccine (0.5ml) + intradermal saline at inclusion and after 3 months.
Trial: NCT06672575
Drug: Ivonescimab
RxNorm normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participante will recived an infusion by vein
Trial: NCT00751894
Drug: Pegfilgrastim (Neulasta, Amgen)
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sequential Bayesian study
Trial: NCT05658380
Drug: atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive 0.01 mg/kg intravenous atropine in 5 ml normal saline 0.9 % before induction of spinal anaesthesia
Trial: NCT06487156
Drug: Nivolumab + ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As per product label
Trial: NCT04609748
Drug: Cannabidiol Oil
RxNorm normalized name: CANNABIDIOL OIL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol oil will be given twice a day, in a dose of 33,6mg, applied orally. The therapy will last 15 days.
Trial: NCT04609748
Drug: Nimesulide
RxNorm normalized name: nimesulide
DrugBank: Nimesulide (DB04743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimessulid will be given twice a day - 2x100mg, applied orally. The therapy will last 15 days.
Trial: NCT05089708
Drug: Trifarotene Cream
RxNorm normalized name: trifarotene
DrugBank: Trifarotene (DB12808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks
Trial: NCT05089708
Drug: Trifarotene Vehicle Cream
RxNorm normalized name: trifarotene
DrugBank: Trifarotene (DB12808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks
Trial: NCT06672445
Drug: ARO-ATXN2 Injection
RxNorm normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of ARO-ATXN2 by intrathecal (IT) administration
Trial: NCT04364620
Drug: AB-16B5
RxNorm normalized name: Immunoglobulin g2, anti-(human clusterin .beta.-chain) (human-mus musculus monoclonal ab-16b5 .gamma.2-chain), disulfide with human-mus musculus monoclonal ab-16b5 .kappa.-chain, dimer
DrugBank: Sotevtamab (DB19120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB-16B5 is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU).
Trial: NCT04364620
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel is an anticancer chemotherapy drug approved in the treatment of non-small cell lung cancer
Trial: NCT06542653
Drug: OMT
RxNorm normalized name: Comtan
DrugBank: Entacapone (DB00494)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: optimal medical therapy (OMT) in CTO patients, such as aspirin 1td, ACEI/ARB 1td, β blocker 1td, statin 1td.
Trial: NCT05215197
Drug: intracochlear platelet rich fibrin administration
RxNorm normalized name: platelet glycoprotein VI
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intracochlear platelet rich fibrin administration during routine cochlear implantation surgery
Trial: NCT06616194
Drug: Rimegepant
RxNorm normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg orally disintegrating tablets
Trial: NCT06033196
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The initial dose of tocilizumab will be administered in the operating room before reperfusion of the first lung during the lung transplant surgery.~6 doses will be given once every four weeks over a 20-week period. The dose is approved for pediatric patients who weigh 30 kg or more
Trial: NCT06033196
Drug: Placebo for Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo 0.9% Sodium Chloride Injection USP (Normal Saline)~Placebo will be given as a single intravenous dose, volume matched to tocilizumab. Placebo will be administered over a period of approximately 60 minutes; once every four weeks over a 20-week period. The first placebo dose will be during the transplant surgery before reperfusion of the first lung allograft, with 5 subsequent monthly doses
Trial: NCT05334329
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05827874
Drug: Nipocalimab
RxNorm normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nipocalimab will be administered as an IV infusion.
Trial: NCT05394857
Drug: SHR-1314
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1314 subcutaneously
Trial: NCT06664853
Drug: Dexamethasone sodium phosphate
RxNorm normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone Sodium Phosphate encapsulated in autologous erythrocytes and administered via intravenous (IV) infusion
Trial: NCT06666348
Drug: Mirdametinib
RxNorm normalized name: Mirdametinib
DrugBank: Mirdametinib (DB07101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive orally administered mirdametinib in combination with intravenous vinblastine chemotherapy
Trial: NCT04869488
Drug: Fluzoparib
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzoparib Orally twice daily（Cohort 1、Cohort 4）
Trial: NCT04869488
Drug: Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets
RxNorm normalized name: Abiraterone Acetate
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Enzalutamide OR abiraterone acetate Orally once daily（Cohort 1）
Trial: NCT04869488
Drug: Fluzoparib Combined With Apatinib
RxNorm normalized name: aminophenazone, combinations with psycholeptics
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzoparib Orally twice daily; Apatinib Orally once daily（Cohort 2、Cohort 3、Cohort 4）
Trial: NCT06388824
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients undergoing surgical abortion received a single injection of 0.2mg/kg esketamine after the beginning of surgery